{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:20:11Z","timestamp":1795029611463,"version":"4.10.2"},"reference-count":307,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Muscle wasting is a consequence of physiological changes or a pathology characterized by increased catabolic activity that leads to progressive loss of skeletal muscle mass and strength. Numerous diseases, including cancer, organ failure, infection, and aging-associated diseases, are associated with muscle wasting. Cancer cachexia is a multifactorial syndrome characterized by loss of skeletal muscle mass, with or without the loss of fat mass, resulting in functional impairment and reduced quality of life. It is caused by the upregulation of systemic inflammation and catabolic stimuli, leading to inhibition of protein synthesis and enhancement of muscle catabolism. Here, we summarize the complex molecular networks that regulate muscle mass and function. Moreover, we describe complex multi-organ roles in cancer cachexia. Although cachexia is one of the main causes of cancer-related deaths, there are still no approved drugs for cancer cachexia. Thus, we compiled recent ongoing pre-clinical and clinical trials and further discussed potential therapeutic approaches for cancer cachexia.<\/jats:p>","DOI":"10.1186\/s13045-023-01454-0","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T15:01:59Z","timestamp":1684767719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":335,"title":["Cancer cachexia: molecular mechanisms and treatment strategies"],"prefix":"10.1186","volume":"16","author":[{"given":"Tania","family":"Setiawan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ita Novita","family":"Sari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoseph Toni","family":"Wijaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadya Marcelina","family":"Julianto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jabir Aliyu","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Heon","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyog Young","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"issue":"1","key":"1454_CR1","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/s41467-020-20760-6","volume":"12","author":"F Relaix","year":"2021","unstructured":"Relaix F, et al. Perspectives on skeletal muscle stem cells. Nat Commun. 2021;12(1):692.","journal-title":"Nat Commun"},{"key":"1454_CR2","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.RA120.002166","volume":"20","author":"R Blazev","year":"2021","unstructured":"Blazev R, et al. Integrated Glycoproteomics identifies a role of n-glycosylation and galectin-1 on myogenesis and muscle development. Mol Cell Proteomics. 2021;20: 100030.","journal-title":"Mol Cell Proteomics"},{"issue":"7","key":"1454_CR3","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.3390\/cells9071658","volume":"9","author":"KW Jorgenson","year":"2020","unstructured":"Jorgenson KW, Phillips SM, Hornberger TA. Identifying the Structural adaptations that drive the mechanical load-induced growth of skeletal muscle: a scoping review. Cells. 2020;9(7):1658.","journal-title":"Cells"},{"issue":"1","key":"1454_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12915-021-01091-4","volume":"19","author":"L Coudert","year":"2021","unstructured":"Coudert L, et al. The ESCRT-0 subcomplex component Hrs\/Hgs is a master regulator of myogenesis via modulation of signaling and degradation pathways. BMC Biol. 2021;19(1):153.","journal-title":"BMC Biol"},{"key":"1454_CR5","unstructured":"Shukuya T, et al., Epidemiology, risk factors and impact of cachexia on patient outcome: Results from the Japanese Lung Cancer Registry Study. J Cachexia, Sarcopenia and Muscle. n\/a(n\/a)."},{"issue":"2","key":"1454_CR6","doi-asserted-by":"publisher","first-page":"511","DOI":"10.21873\/anticanres.16188","volume":"43","author":"H Watanabe","year":"2023","unstructured":"Watanabe H, Oshima T. The latest treatments for cancer cachexia: an overview. Anticancer Res. 2023;43(2):511\u201321.","journal-title":"Anticancer Res"},{"issue":"1","key":"1454_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13395-021-00274-5","volume":"11","author":"L Zhou","year":"2021","unstructured":"Zhou L, et al. Amiloride ameliorates muscle wasting in cancer cachexia through inhibiting tumor-derived exosome release. Skeletal Muscle. 2021;11(1):17.","journal-title":"Skeletal Muscle"},{"issue":"1","key":"1454_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/jcsm.12652","volume":"12","author":"MM Thibaut","year":"2021","unstructured":"Thibaut MM, et al. Inflammation-induced cholestasis in cancer cachexia. J Cachexia Sarcopenia Muscle. 2021;12(1):70\u201390.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"1454_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41574-018-0123-0","volume":"15","author":"JM Argil\u00e9s","year":"2019","unstructured":"Argil\u00e9s JM, et al. Inter-tissue communication in cancer cachexia. Nat Rev Endocrinol. 2019;15(1):9\u201320.","journal-title":"Nat Rev Endocrinol"},{"key":"1454_CR10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.nut.2016.11.008","volume":"35","author":"H Jager-Wittenaar","year":"2017","unstructured":"Jager-Wittenaar H, et al. High prevalence of cachexia in newly diagnosed head and neck cancer patients: an exploratory study. Nutrition. 2017;35:114\u20138.","journal-title":"Nutrition"},{"issue":"1","key":"1454_CR11","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/s41467-020-20123-1","volume":"12","author":"R Sartori","year":"2021","unstructured":"Sartori R, Romanello V, Sandri M. Mechanisms of muscle atrophy and hypertrophy: implications in health and disease. Nat Commun. 2021;12(1):330.","journal-title":"Nat Commun"},{"key":"1454_CR12","unstructured":"Zhang Q, et al., Association of systemic inflammation with survival in patients with cancer cachexia: results from a multicentre cohort study. J Cachexia, Sarcopenia and Muscle. n\/a(n\/a)."},{"issue":"5","key":"1454_CR13","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489\u201395.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1454_CR14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/jcsm.12666","volume":"12","author":"D Neyroud","year":"2021","unstructured":"Neyroud D, et al. FoxP1 is a transcriptional repressor associated with cancer cachexia that induces skeletal muscle wasting and weakness. J Cachexia Sarcopenia Muscle. 2021;12(2):421\u201342.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"1454_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41389-020-00288-6","volume":"10","author":"V Rausch","year":"2021","unstructured":"Rausch V, et al. Understanding the common mechanisms of heart and skeletal muscle wasting in cancer cachexia. Oncogenesis. 2021;10(1):1.","journal-title":"Oncogenesis"},{"key":"1454_CR16","doi-asserted-by":"publisher","first-page":"4251458","DOI":"10.1155\/2022\/4251458","volume":"2022","author":"Y Tang","year":"2022","unstructured":"Tang Y, et al. Analysis of acupoints combination for cancer-related anorexia based on association rule mining. Evid Based Complement Altern Med. 2022;2022:4251458.","journal-title":"Evid Based Complement Altern Med"},{"key":"1454_CR17","doi-asserted-by":"crossref","unstructured":"Xi S, et al. The Ciji-Hua\u2019ai-Baosheng II formula attenuates chemotherapy-induced anorexia in mice With H22 hepatocellular carcinoma. Front Pharmacol, 2021. 12.","DOI":"10.3389\/fphar.2021.715824"},{"issue":"18","key":"1454_CR18","first-page":"4493","volume":"59","author":"A Inui","year":"1999","unstructured":"Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key?1. Can Res. 1999;59(18):4493\u2013501.","journal-title":"Can Res"},{"issue":"5","key":"1454_CR19","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/jnr.24589","volume":"98","author":"U Tural","year":"2020","unstructured":"Tural U, Iosifescu DV. Neuropeptide Y in PTSD, MDD, and chronic stress: a systematic review and meta-analysis. J Neurosci Res. 2020;98(5):950\u201363.","journal-title":"J Neurosci Res"},{"issue":"2","key":"1454_CR20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00125-020-05327-w","volume":"64","author":"R Nogueiras","year":"2021","unstructured":"Nogueiras R, Sabio G. Brain JNK and metabolic disease. Diabetologia. 2021;64(2):265\u201374.","journal-title":"Diabetologia"},{"issue":"1\u20132","key":"1454_CR21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000501023","volume":"110","author":"DS Razolli","year":"2020","unstructured":"Razolli DS, et al. Proopiomelanocortin Processing in the Hypothalamus Is Directly Regulated by Saturated Fat: Implications for the Development of Obesity. Neuroendocrinology. 2020;110(1\u20132):92\u2013104.","journal-title":"Neuroendocrinology"},{"issue":"3","key":"1454_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1615\/CritRevOncog.v17.i3.20","volume":"17","author":"A Laviano","year":"2012","unstructured":"Laviano A, et al. Neuroinflammation: a contributing factor to the pathogenesis of cancer cachexia. Crit Rev Oncog. 2012;17(3):247\u201351.","journal-title":"Crit Rev Oncog"},{"issue":"9","key":"1454_CR23","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.1172\/JCI138392","volume":"130","author":"X Zhu","year":"2020","unstructured":"Zhu X, et al. Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease\u2013associated cachexia. J Clin Investig. 2020;130(9):4921\u201334.","journal-title":"J Clin Investig"},{"issue":"3","key":"1454_CR24","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1530\/JOE-15-0170","volume":"226","author":"MC Mendes","year":"2015","unstructured":"Mendes MC, et al. Molecular and neuroendocrine mechanisms of cancer cachexia. J Endocrinol. 2015;226(3):R29-43.","journal-title":"J Endocrinol"},{"key":"1454_CR25","doi-asserted-by":"publisher","first-page":"108289","DOI":"10.1016\/j.neuropharm.2020.108289","volume":"180","author":"K Navarro I Batista","year":"2020","unstructured":"Navarro I Batista K, Schraner M, Riediger T. Brainstem prolactin-releasing peptide contributes to cancer anorexia-cachexia syndrome in rats. Neuropharmacology. 2020;180:108289.","journal-title":"Neuropharmacology"},{"issue":"5","key":"1454_CR26","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/nn1455","volume":"8","author":"RD Cone","year":"2005","unstructured":"Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci. 2005;8(5):571\u20138.","journal-title":"Nat Neurosci"},{"issue":"4","key":"1454_CR27","first-page":"1432","volume":"61","author":"DL Marks","year":"2001","unstructured":"Marks DL, Ling N, Cone RD. Role of the central melanocortin system in cachexia. Cancer Res. 2001;61(4):1432\u20138.","journal-title":"Cancer Res"},{"issue":"2","key":"1454_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","volume":"16","author":"KC Fearon","year":"2012","unstructured":"Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16(2):153\u201366.","journal-title":"Cell Metab"},{"issue":"5","key":"1454_CR29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1101\/gad.276733.115","volume":"30","author":"M Petruzzelli","year":"2016","unstructured":"Petruzzelli M, Wagner EF. Mechanisms of metabolic dysfunction in cancer-associated cachexia. Genes Dev. 2016;30(5):489\u2013501.","journal-title":"Genes Dev"},{"issue":"4","key":"1454_CR30","first-page":"265","volume":"1","author":"DP Behan","year":"1996","unstructured":"Behan DP, et al. Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders. Mol Psychiatry. 1996;1(4):265\u201377.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"1454_CR31","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3322\/canjclin.52.2.72","volume":"52","author":"A Inui","year":"2002","unstructured":"Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin. 2002;52(2):72\u201391.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"1454_CR32","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1093\/ajcn\/83.4.735","volume":"83","author":"JE Morley","year":"2006","unstructured":"Morley JE, Thomas DR, Wilson M-MG. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006;83(4):735\u201343.","journal-title":"Am J Clin Nutr"},{"issue":"8","key":"1454_CR33","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.psyneuen.2010.02.003","volume":"35","author":"A Asakawa","year":"2010","unstructured":"Asakawa A, et al. Parathyroid hormone-related protein has an anorexigenic activity via activation of hypothalamic urocortins 2 and 3. Psychoneuroendocrinology. 2010;35(8):1178\u201386.","journal-title":"Psychoneuroendocrinology"},{"issue":"7516","key":"1454_CR34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature13528","volume":"513","author":"S Kir","year":"2014","unstructured":"Kir S, et al. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature. 2014;513(7516):100\u20134.","journal-title":"Nature"},{"issue":"16","key":"1454_CR35","doi-asserted-by":"publisher","first-page":"8491","DOI":"10.3390\/ijms22168491","volume":"22","author":"H Nishikawa","year":"2021","unstructured":"Nishikawa H, et al. Cancer cachexia: its mechanism and clinical significance. Int J Mol Sci. 2021;22(16):8491.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1454_CR36","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1210\/jc.2004-1788","volume":"90","author":"JM Garcia","year":"2005","unstructured":"Garcia JM, et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab. 2005;90(5):2920\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1454_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2016.3","volume":"5","author":"PE Porporato","year":"2016","unstructured":"Porporato PE. Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 2016;5(2): e200.","journal-title":"Oncogenesis"},{"issue":"1","key":"1454_CR38","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2337\/db13-0414","volume":"63","author":"KM Heppner","year":"2014","unstructured":"Heppner KM, et al. Both acyl and des-acyl ghrelin regulate adiposity and glucose metabolism via central nervous system ghrelin receptors. Diabetes. 2014;63(1):122\u201331.","journal-title":"Diabetes"},{"issue":"2","key":"1454_CR39","first-page":"611","volume":"123","author":"PE Porporato","year":"2013","unstructured":"Porporato PE, et al. Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. J Clin Invest. 2013;123(2):611\u201322.","journal-title":"J Clin Invest"},{"issue":"12","key":"1454_CR40","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.1210\/jc.2004-0613","volume":"89","author":"DH St-Pierre","year":"2004","unstructured":"St-Pierre DH, et al. Relationship between ghrelin and energy expenditure in healthy young women. J Clin Endocrinol Metab. 2004;89(12):5993\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1454_CR41","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/cncr.21690","volume":"106","author":"I Wolf","year":"2006","unstructured":"Wolf I, et al. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer. 2006;106(4):966\u201373.","journal-title":"Cancer"},{"issue":"2","key":"1454_CR42","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/jb\/mvr134","volume":"151","author":"T Sato","year":"2012","unstructured":"Sato T, et al. Structure, regulation and function of ghrelin. J Biochem. 2012;151(2):119\u201328.","journal-title":"J Biochem"},{"issue":"2","key":"1454_CR43","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3892\/etm.2017.4615","volume":"14","author":"F Li","year":"2017","unstructured":"Li F, et al. Ginsenoside Rg1 prevents starvation-induced muscle protein degradation via regulation of AKT\/mTOR\/FoxO signaling in C2C12 myotubes. Exp Ther Med. 2017;14(2):1241\u20137.","journal-title":"Exp Ther Med"},{"issue":"2","key":"1454_CR44","doi-asserted-by":"publisher","first-page":"188359","DOI":"10.1016\/j.bbcan.2020.188359","volume":"1873","author":"JA Siddiqui","year":"2020","unstructured":"Siddiqui JA, et al. Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions. Biochimica Biophys Acta BBA Rev Cancer. 2020;1873(2):188359.","journal-title":"Biochimica Biophys Acta BBA Rev Cancer"},{"issue":"1","key":"1454_CR45","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1172\/JCI200421134","volume":"114","author":"VD Dixit","year":"2004","unstructured":"Dixit VD, et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Investig. 2004;114(1):57\u201366.","journal-title":"J Clin Investig"},{"issue":"2","key":"1454_CR46","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/jcsm.12023","volume":"6","author":"J-A Chen","year":"2015","unstructured":"Chen J-A, et al. Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. J Cachexia Sarcopenia Muscle. 2015;6(2):132\u201343.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"1454_CR47","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1358\/dot.2022.58.3.3381585","volume":"58","author":"K Nishie","year":"2022","unstructured":"Nishie K, Sato S, Hanaoka M. Anamorelin for cancer cachexia. Drugs Today (Barc). 2022;58(3):97\u2013104.","journal-title":"Drugs Today (Barc)"},{"issue":"1","key":"1454_CR48","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00520-012-1500-1","volume":"21","author":"JM Garcia","year":"2013","unstructured":"Garcia JM, Friend J, Allen S. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Supp Care Cancer. 2013;21(1):129\u201337.","journal-title":"Supp Care Cancer"},{"issue":"1","key":"1454_CR49","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1470-2045(14)71154-4","volume":"16","author":"JM Garcia","year":"2015","unstructured":"Garcia JM, et al. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol. 2015;16(1):108\u201316.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1454_CR50","first-page":"774","volume":"9","author":"Y Shimizu","year":"2003","unstructured":"Shimizu Y, et al. Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res. 2003;9(2):774\u20138.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1454_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173113","volume":"12","author":"K Terawaki","year":"2017","unstructured":"Terawaki K, et al. Development of ghrelin resistance in a cancer cachexia rat model using human gastric cancer-derived 85As2 cells and the palliative effects of the Kampo medicine rikkunshito on the model. PLoS ONE. 2017;12(3): e0173113.","journal-title":"PLoS ONE"},{"issue":"1","key":"1454_CR52","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41419-020-03382-0","volume":"12","author":"W Hu","year":"2021","unstructured":"Hu W, et al. Extracellular vesicles-released parathyroid hormone-related protein from Lewis lung carcinoma induces lipolysis and adipose tissue browning in cancer cachexia. Cell Death Dis. 2021;12(1):134.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1454_CR53","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/jcsm.12893","volume":"13","author":"A Molfino","year":"2022","unstructured":"Molfino A, et al. Histomorphological and inflammatory changes of white adipose tissue in gastrointestinal cancer patients with and without cachexia. J Cachexia Sarcopenia Muscle. 2022;13(1):333\u201342.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"1454_CR54","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12885-017-3178-8","volume":"17","author":"MJ Alves","year":"2017","unstructured":"Alves MJ, et al. Adipose tissue fibrosis in human cancer cachexia: the role of TGF\u03b2 pathway. BMC Cancer. 2017;17(1):190.","journal-title":"BMC Cancer"},{"issue":"6039","key":"1454_CR55","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1126\/science.1198973","volume":"333","author":"SK Das","year":"2011","unstructured":"Das SK, et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science. 2011;333(6039):233\u20138.","journal-title":"Science"},{"issue":"2","key":"1454_CR56","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/jcsm.12864","volume":"13","author":"Y Luan","year":"2022","unstructured":"Luan Y, et al. Development of ovarian tumour causes significant loss of muscle and adipose tissue: a novel mouse model for cancer cachexia study. J Cachexia Sarcopenia Muscle. 2022;13(2):1289\u2013301.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"1454_CR57","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12986-022-00694-0","volume":"19","author":"SA Machado","year":"2022","unstructured":"Machado SA, et al. Browning of the white adipose tissue regulation: new insights into nutritional and metabolic relevance in health and diseases. Nutr Metab. 2022;19(1):61.","journal-title":"Nutr Metab"},{"issue":"5","key":"1454_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107598","volume":"31","author":"A Guilherme","year":"2020","unstructured":"Guilherme A, et al. Control of adipocyte thermogenesis and lipogenesis through \u03b23-adrenergic and thyroid hormone signal integration. Cell Rep. 2020;31(5): 107598.","journal-title":"Cell Rep"},{"issue":"9","key":"1454_CR59","doi-asserted-by":"publisher","first-page":"5156","DOI":"10.1016\/j.clnu.2021.08.003","volume":"40","author":"J Han","year":"2021","unstructured":"Han J, et al. Subcutaneous, but not visceral, adipose tissue as a marker for prognosis in gastric cancer patients with cachexia. Clin Nutr. 2021;40(9):5156\u201361.","journal-title":"Clin Nutr"},{"issue":"1","key":"1454_CR60","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/jcp.26811","volume":"234","author":"SI Daas","year":"2019","unstructured":"Daas SI, Rizeq BR, Nasrallah GK. Adipose tissue dysfunction in cancer cachexia. J Cell Physiol. 2019;234(1):13\u201322.","journal-title":"J Cell Physiol"},{"issue":"11","key":"1454_CR61","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1002\/jcb.29682","volume":"121","author":"F de Fatima Silva","year":"2020","unstructured":"de Fatima Silva F, et al. Akt activation by insulin treatment attenuates cachexia in Walker-256 tumor-bearing rats. J Cell Biochem. 2020;121(11):4558\u201368.","journal-title":"J Cell Biochem"},{"issue":"6","key":"1454_CR62","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.3390\/ijms23063004","volume":"23","author":"GD Mangano","year":"2022","unstructured":"Mangano GD, et al. Cancer-related cachexia: the vicious circle between inflammatory cytokines, skeletal muscle, lipid metabolism and the possible role of physical training. Int J Mol Sci. 2022;23(6):3004.","journal-title":"Int J Mol Sci"},{"key":"1454_CR63","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.lfs.2016.11.033","volume":"170","author":"HJ Patel","year":"2017","unstructured":"Patel HJ, Patel BM. TNF-\u03b1 and cancer cachexia: Molecular insights and clinical implications. Life Sci. 2017;170:56\u201363.","journal-title":"Life Sci"},{"key":"1454_CR64","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.abb.2014.12.026","volume":"567","author":"AI Padrao","year":"2015","unstructured":"Padrao AI, et al. Endurance training prevents TWEAK but not myostatin-mediated cardiac remodelling in cancer cachexia. Arch Biochem Biophys. 2015;567:13\u201321.","journal-title":"Arch Biochem Biophys"},{"issue":"11","key":"1454_CR65","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1016\/j.celrep.2017.11.038","volume":"21","author":"S Das","year":"2017","unstructured":"Das S, et al. ATP citrate lyase regulates myofiber differentiation and increases regeneration by altering histone acetylation. Cell Rep. 2017;21(11):3003\u201311.","journal-title":"Cell Rep"},{"issue":"3","key":"1454_CR66","doi-asserted-by":"publisher","first-page":"C706","DOI":"10.1152\/ajpcell.00626.2008","volume":"297","author":"W Li","year":"2009","unstructured":"Li W, et al. Interleukin-1 stimulates catabolism in C2C12 myotubes. Am J Physiol Cell Physiol. 2009;297(3):C706\u201314.","journal-title":"Am J Physiol Cell Physiol"},{"key":"1454_CR67","doi-asserted-by":"crossref","unstructured":"Callaway CS, et al., IL-8 released from human pancreatic cancer and tumor-associated stromal cells signals through a CXCR2-ERK1\/2 axis to induce muscle atrophy. Cancers (Basel), 2019. 11(12).","DOI":"10.3390\/cancers11121863"},{"key":"1454_CR68","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.canlet.2020.04.017","volume":"484","author":"SK Shukla","year":"2020","unstructured":"Shukla SK, et al. Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia. Cancer Lett. 2020;484:29\u201339.","journal-title":"Cancer Lett"},{"issue":"12","key":"1454_CR69","doi-asserted-by":"publisher","first-page":"6111","DOI":"10.4049\/jimmunol.1302895","volume":"192","author":"AG Cuenca","year":"2014","unstructured":"Cuenca AG, et al. Novel role for tumor-induced expansion of myeloid-derived cells in cancer cachexia. J Immunol. 2014;192(12):6111\u20139.","journal-title":"J Immunol"},{"issue":"7","key":"1454_CR70","doi-asserted-by":"publisher","first-page":"4676","DOI":"10.4049\/jimmunol.181.7.4676","volume":"181","author":"Z Wang","year":"2008","unstructured":"Wang Z, et al. A novel role for CD4+ T cells in the control of cachexia. J Immunol. 2008;181(7):4676\u201384.","journal-title":"J Immunol"},{"issue":"8","key":"1454_CR71","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.micinf.2015.04.002","volume":"17","author":"JE Olgu\u00edn","year":"2015","unstructured":"Olgu\u00edn JE, et al. Adoptive transfer of CD4+Foxp3+ regulatory T cells to C57BL\/6J mice during acute infection with Toxoplasma gondii down modulates the exacerbated Th1 immune response. Microbes Infect. 2015;17(8):586\u201395.","journal-title":"Microbes Infect"},{"issue":"1","key":"1454_CR72","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13395-019-0209-y","volume":"9","author":"A Anoveros-Barrera","year":"2019","unstructured":"Anoveros-Barrera A, et al. Immunohistochemical phenotyping of T cells, granulocytes, and phagocytes in the muscle of cancer patients: association with radiologically defined muscle mass and gene expression. Skeletal Muscle. 2019;9(1):24.","journal-title":"Skeletal Muscle"},{"issue":"26","key":"1454_CR73","doi-asserted-by":"publisher","first-page":"18224","DOI":"10.18632\/oncotarget.24804","volume":"9","author":"LB Bindels","year":"2018","unstructured":"Bindels LB, et al. Increased gut permeability in cancer cachexia: mechanisms and clinical relevance. Oncotarget. 2018;9(26):18224\u201338.","journal-title":"Oncotarget"},{"issue":"6","key":"1454_CR74","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1002\/jcsm.12776","volume":"12","author":"J Poisson","year":"2021","unstructured":"Poisson J, et al. Prevalence and prognostic impact of cachexia among older patients with cancer: a nationwide cross-sectional survey (NutriAgeCancer). J Cachexia Sarcopenia Muscle. 2021;12(6):1477\u201388.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"1454_CR75","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/s12877-022-02981-0","volume":"22","author":"M Victoria","year":"2022","unstructured":"Victoria M, et al. Gut microbiota alterations in critically ill older patients: a multicenter study. BMC Geriatr. 2022;22(1):373.","journal-title":"BMC Geriatr"},{"issue":"8","key":"1454_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0126-x","volume":"50","author":"C Chelakkot","year":"2018","unstructured":"Chelakkot C, Ghim J, Ryu SH. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med. 2018;50(8):1\u20139.","journal-title":"Exp Mol Med"},{"issue":"12","key":"1454_CR77","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.bbadis.2011.08.010","volume":"1812","author":"MJ Puppa","year":"2011","unstructured":"Puppa MJ, et al. Gut barrier dysfunction in the ApcMin\/+ mouse model of colon cancer cachexia. Biochimica et Biophysica Acta BBA Mol Basis Disease. 2011;1812(12):1601\u20136.","journal-title":"Biochimica et Biophysica Acta BBA Mol Basis Disease"},{"issue":"12","key":"1454_CR78","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.trecan.2018.10.001","volume":"4","author":"SF Schmidt","year":"2018","unstructured":"Schmidt SF, et al. Cancer cachexia: more than skeletal muscle wasting. Trends in Cancer. 2018;4(12):849\u201360.","journal-title":"Trends in Cancer"},{"issue":"12","key":"1454_CR79","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1152\/physiolgenomics.00128.2014","volume":"47","author":"AM Shum","year":"2015","unstructured":"Shum AM, et al. Cardiac and skeletal muscles show molecularly distinct responses to cancer cachexia. Physiol Genom. 2015;47(12):588\u201399.","journal-title":"Physiol Genom"},{"key":"1454_CR80","doi-asserted-by":"crossref","unstructured":"Bordignon C, Dos Santos BS, Rosa DD, Impact of cancer cachexia on cardiac and skeletal muscle: role of exercise training. Cancers (Basel), 2022. 14(2).","DOI":"10.3390\/cancers14020342"},{"issue":"5","key":"1454_CR81","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.3892\/or.2017.5542","volume":"37","author":"Y Belloum","year":"2017","unstructured":"Belloum Y, Rannou-Bekono F, Favier FB. Cancer-induced cardiac cachexia: Pathogenesis and impact of physical activity (Review). Oncol Rep. 2017;37(5):2543\u201352.","journal-title":"Oncol Rep"},{"issue":"8","key":"1454_CR82","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.bbadis.2013.03.018","volume":"1832","author":"AH Remels","year":"2013","unstructured":"Remels AH, et al. Regulation of skeletal muscle oxidative phenotype by classical NF-kappaB signalling. Biochim Biophys Acta. 2013;1832(8):1313\u201325.","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"1454_CR83","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1172\/JCI58662","volume":"121","author":"M Tran","year":"2011","unstructured":"Tran M, et al. PGC-1alpha promotes recovery after acute kidney injury during systemic inflammation in mice. J Clin Invest. 2011;121(10):4003\u201314.","journal-title":"J Clin Invest"},{"issue":"6","key":"1454_CR84","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/jcsm.12233","volume":"8","author":"TS Bowen","year":"2017","unstructured":"Bowen TS, et al. Small-molecule inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia. J Cachexia Sarcopenia Muscle. 2017;8(6):939\u201353.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"2","key":"1454_CR85","doi-asserted-by":"publisher","first-page":"R519","DOI":"10.1152\/ajpregu.00458.2001","volume":"282","author":"A Dirks","year":"2002","unstructured":"Dirks A, Leeuwenburgh C. Apoptosis in skeletal muscle with aging. Am J Physiol Regul Integr Comp Physiol. 2002;282(2):R519\u201327.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"20","key":"1454_CR86","doi-asserted-by":"publisher","first-page":"9035","DOI":"10.1073\/pnas.0914013107","volume":"107","author":"Y Chen","year":"2010","unstructured":"Chen Y, et al. Dual autonomous mitochondrial cell death pathways are activated by Nix\/BNip3L and induce cardiomyopathy. Proc Natl Acad Sci. 2010;107(20):9035\u201342.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"1454_CR87","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1161\/CIRCRESAHA.116.303554","volume":"116","author":"GW Dorn","year":"2015","unstructured":"Dorn GW, Kitsis RN. The mitochondrial dynamism-mitophagy-cell death interactome. Circ Res. 2015;116(1):167\u201382.","journal-title":"Circ Res"},{"issue":"8","key":"1454_CR88","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jacbts.2021.05.008","volume":"6","author":"A Karlstaedt","year":"2021","unstructured":"Karlstaedt A, et al. Cardio-oncology: understanding the intersections between cardiac metabolism and cancer biology. JACC Basic Transl Sci. 2021;6(8):705\u201318.","journal-title":"JACC Basic Transl Sci"},{"issue":"7","key":"1454_CR89","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1161\/CIRCULATIONAHA.120.048655","volume":"142","author":"J Moslehi","year":"2020","unstructured":"Moslehi J, Zhang Q, Moore KJ. Crosstalk between the heart and cancer: beyond drug toxicity. Circulation. 2020;142(7):684\u20137.","journal-title":"Circulation"},{"issue":"8","key":"1454_CR90","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00109-007-0220-3","volume":"85","author":"M-A Weber","year":"2007","unstructured":"Weber M-A, et al. Myoglobin plasma level related to muscle mass and fiber composition \u2013 a clinical marker of muscle wasting? J Mol Med. 2007;85(8):887\u201396.","journal-title":"J Mol Med"},{"issue":"4","key":"1454_CR91","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.clnu.2011.12.008","volume":"31","author":"NA Stephens","year":"2012","unstructured":"Stephens NA, et al. Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function. Clin Nutr. 2012;31(4):499\u2013505.","journal-title":"Clin Nutr"},{"issue":"2","key":"1454_CR92","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/jcsm.12678","volume":"12","author":"A Martin","year":"2021","unstructured":"Martin A, Freyssenet D. Phenotypic features of cancer cachexia-related loss of skeletal muscle mass and function: lessons from human and animal studies. J Cachexia Sarcopenia Muscle. 2021;12(2):252\u201373.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"6","key":"1454_CR93","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.3892\/mmr.2020.11608","volume":"22","author":"W Yang","year":"2020","unstructured":"Yang W, et al. Molecular mechanisms of cancer cachexiainduced muscle atrophy (Review). Mol Med Rep. 2020;22(6):4967\u201380.","journal-title":"Mol Med Rep"},{"issue":"1","key":"1454_CR94","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12576-020-00768-9","volume":"70","author":"Y Kitajima","year":"2020","unstructured":"Kitajima Y, Yoshioka K, Suzuki N. The ubiquitin-proteasome system in regulation of the skeletal muscle homeostasis and atrophy: from basic science to disorders. J Physiol Sci. 2020;70(1):40.","journal-title":"J Physiol Sci"},{"issue":"1","key":"1454_CR95","doi-asserted-by":"publisher","first-page":"e13064","DOI":"10.1111\/acel.13064","volume":"19","author":"W-M Chen","year":"2020","unstructured":"Chen W-M, et al. Lysophosphatidic acid receptor LPA(3) prevents oxidative stress and cellular senescence in Hutchinson-Gilford progeria syndrome. Aging Cell. 2020;19(1):e13064\u2013e13064.","journal-title":"Aging Cell"},{"issue":"26","key":"1454_CR96","doi-asserted-by":"publisher","first-page":"E5266","DOI":"10.1073\/pnas.1620013114","volume":"114","author":"JL Chen","year":"2017","unstructured":"Chen JL, et al. Specific targeting of TGF-\u03b2 family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. Proc Natl Acad Sci. 2017;114(26):E5266\u201375.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"1454_CR97","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1093\/ajcn\/nqz347","volume":"111","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, et al. The autophagic-lysosomal and ubiquitin proteasome systems are simultaneously activated in the skeletal muscle of gastric cancer patients with cachexia. Am J Clin Nutr. 2020;111(3):570\u20139.","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"1454_CR98","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/jcsm.12043","volume":"6","author":"TS Bowen","year":"2015","unstructured":"Bowen TS, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle. 2015;6(3):197\u2013207.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"6","key":"1454_CR99","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.cmet.2007.11.001","volume":"6","author":"C Mammucari","year":"2007","unstructured":"Mammucari C, et al. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab. 2007;6(6):458\u201371.","journal-title":"Cell Metab"},{"issue":"2","key":"1454_CR100","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/rco2.30","volume":"4","author":"Z Cao","year":"2021","unstructured":"Cao Z, et al. Mediators and clinical treatment for cancer cachexia: a systematic review. JCSM Rapid Commun. 2021;4(2):166\u201386.","journal-title":"JCSM Rapid Commun"},{"issue":"4","key":"1454_CR101","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S0039-6060(99)70131-5","volume":"126","author":"A Williams","year":"1999","unstructured":"Williams A, et al. The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery. 1999;126(4):744\u20139.","journal-title":"Surgery"},{"issue":"3","key":"1454_CR102","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/01.SLA.0000055225.96357.71","volume":"237","author":"M Bossola","year":"2003","unstructured":"Bossola M, et al. Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg. 2003;237(3):384\u20139.","journal-title":"Ann Surg"},{"issue":"5547","key":"1454_CR103","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1126\/science.1065874","volume":"294","author":"SC Bodine","year":"2001","unstructured":"Bodine SC, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001;294(5547):1704\u20138.","journal-title":"Science"},{"key":"1454_CR104","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.freeradbiomed.2015.12.031","volume":"98","author":"O Rom","year":"2016","unstructured":"Rom O, Reznick AZ. The role of E3 ubiquitin-ligases MuRF-1 and MAFbx in loss of skeletal muscle mass. Free Radic Biol Med. 2016;98:218\u201330.","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"1454_CR105","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cell.2004.09.027","volume":"119","author":"D Cai","year":"2004","unstructured":"Cai D, et al. IKKbeta\/NF-kappaB activation causes severe muscle wasting in mice. Cell. 2004;119(2):285\u201398.","journal-title":"Cell"},{"key":"1454_CR106","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/978-94-007-6627-3_2","volume":"788","author":"S Kaisari","year":"2013","unstructured":"Kaisari S, et al. Involvement of NF-kappaB and muscle specific E3 ubiquitin ligase MuRF1 in cigarette smoke-induced catabolism in C2 myotubes. Adv Exp Med Biol. 2013;788:7\u201317.","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"1454_CR107","doi-asserted-by":"publisher","first-page":"C542","DOI":"10.1152\/ajpcell.00192.2009","volume":"298","author":"JM McClung","year":"2010","unstructured":"McClung JM, et al. p38 MAPK links oxidative stress to autophagy-related gene expression in cachectic muscle wasting. Am J Physiol Cell Physiol. 2010;298(3):C542\u20139.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"1454_CR108","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1242\/dmm.010389","volume":"6","author":"P Bonaldo","year":"2013","unstructured":"Bonaldo P, Sandri M. Cellular and molecular mechanisms of muscle atrophy. Dis Model Mech. 2013;6(1):25\u201339.","journal-title":"Dis Model Mech"},{"issue":"6","key":"1454_CR109","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.cmet.2009.10.008","volume":"10","author":"E Masiero","year":"2009","unstructured":"Masiero E, et al. Autophagy is required to maintain muscle mass. Cell Metab. 2009;10(6):507\u201315.","journal-title":"Cell Metab"},{"issue":"3","key":"1454_CR110","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1091\/mbc.e03-09-0704","volume":"15","author":"N Mizushima","year":"2004","unstructured":"Mizushima N, et al. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell. 2004;15(3):1101\u201311.","journal-title":"Mol Biol Cell"},{"issue":"6","key":"1454_CR111","doi-asserted-by":"publisher","first-page":"986","DOI":"10.4161\/auto.28390","volume":"10","author":"M Boyer-Guittaut","year":"2014","unstructured":"Boyer-Guittaut M, et al. The role of GABARAPL1\/GEC1 in autophagic flux and mitochondrial quality control in MDA-MB-436 breast cancer cells. Autophagy. 2014;10(6):986\u20131003.","journal-title":"Autophagy"},{"issue":"6","key":"1454_CR112","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.3945\/ajcn.113.063859","volume":"98","author":"N Tardif","year":"2013","unstructured":"Tardif N, et al. Autophagic-lysosomal pathway is the main proteolytic system modified in the skeletal muscle of esophageal cancer patients. Am J Clin Nutr. 2013;98(6):1485\u201392.","journal-title":"Am J Clin Nutr"},{"issue":"15","key":"1454_CR113","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1016\/j.jmb.2019.05.032","volume":"431","author":"F Penna","year":"2019","unstructured":"Penna F, et al. Autophagy exacerbates muscle wasting in cancer cachexia and impairs mitochondrial function. J Mol Biol. 2019;431(15):2674\u201386.","journal-title":"J Mol Biol"},{"issue":"4","key":"1454_CR114","doi-asserted-by":"publisher","first-page":"527","DOI":"10.4161\/auto.5.4.7962","volume":"5","author":"M Aucello","year":"2009","unstructured":"Aucello M, Dobrowolny G, Musaro A. Localized accumulation of oxidative stress causes muscle atrophy through activation of an autophagic pathway. Autophagy. 2009;5(4):527\u20139.","journal-title":"Autophagy"},{"issue":"4","key":"1454_CR115","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/SPC.0000000000000088","volume":"8","author":"JJ Ceelen","year":"2014","unstructured":"Ceelen JJ, Langen RC, Schols AM. Systemic inflammation in chronic obstructive pulmonary disease and lung cancer: common driver of pulmonary cachexia? Curr Opin Support Palliat Care. 2014;8(4):339\u201345.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"1","key":"1454_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0022-5320(72)80002-9","volume":"39","author":"S Schiaffino","year":"1972","unstructured":"Schiaffino S, Hanzlikova V. Studies on the effect of denervation in developing muscle II The lysosomal system. J Ultrastruct Res. 1972;39(1):1\u201314.","journal-title":"J Ultrastruct Res"},{"issue":"7","key":"1454_CR117","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1054\/bjoc.2001.1696","volume":"84","author":"P Costelli","year":"2001","unstructured":"Costelli P, et al. Activation of Ca(2+)-dependent proteolysis in skeletal muscle and heart in cancer cachexia. Br J Cancer. 2001;84(7):946\u201350.","journal-title":"Br J Cancer"},{"issue":"6","key":"1454_CR118","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1515\/BC.2004.054","volume":"385","author":"A Wendt","year":"2004","unstructured":"Wendt A, Thompson VF, Goll DE. Interaction of calpastatin with calpain: a review. Biol Chem. 2004;385(6):465\u201372.","journal-title":"Biol Chem"},{"issue":"3","key":"1454_CR119","doi-asserted-by":"publisher","first-page":"R580","DOI":"10.1152\/ajpregu.00341.2004","volume":"288","author":"W Wei","year":"2005","unstructured":"Wei W, et al. Sepsis stimulates calpain activity in skeletal muscle by decreasing calpastatin activity but does not activate caspase-3. Am J Physiol Regul Integr Comp Physiol. 2005;288(3):R580\u201390.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"11","key":"1454_CR120","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.exger.2007.08.009","volume":"42","author":"E Dargelos","year":"2007","unstructured":"Dargelos E, et al. Involvement of the calcium-dependent proteolytic system in skeletal muscle aging. Exp Gerontol. 2007;42(11):1088\u201398.","journal-title":"Exp Gerontol"},{"key":"1454_CR121","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3389\/fphys.2017.00213","volume":"8","author":"F Pin","year":"2017","unstructured":"Pin F, et al. Interference with Ca(2+)-dependent proteolysis does not alter the course of muscle wasting in experimental cancer cachexia. Front Physiol. 2017;8:213.","journal-title":"Front Physiol"},{"issue":"11","key":"1454_CR122","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1016\/j.cellsig.2012.07.016","volume":"24","author":"KA Mirza","year":"2012","unstructured":"Mirza KA, Tisdale MJ. Role of Ca2+ in proteolysis-inducing factor (PIF)-induced atrophy of skeletal muscle. Cell Signal. 2012;24(11):2118\u201322.","journal-title":"Cell Signal"},{"issue":"3","key":"1454_CR123","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12943","volume":"18","author":"H Tang","year":"2019","unstructured":"Tang H, et al. mTORC1 underlies age-related muscle fiber damage and loss by inducing oxidative stress and catabolism. Aging Cell. 2019;18(3): e12943.","journal-title":"Aging Cell"},{"issue":"5","key":"1454_CR124","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.cmet.2008.10.002","volume":"8","author":"CF Bentzinger","year":"2008","unstructured":"Bentzinger CF, et al. Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab. 2008;8(5):411\u201324.","journal-title":"Cell Metab"},{"key":"1454_CR125","doi-asserted-by":"publisher","first-page":"ra113","DOI":"10.1126\/scisignal.aab3715","volume":"8","author":"M Guridi","year":"2015","unstructured":"Guridi M, et al. Activation of mTORC1 in skeletal muscle regulates whole-body metabolism through FGF21. Sci Signal. 2015;8:ra113.","journal-title":"Sci Signal"},{"issue":"8","key":"1454_CR126","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1172\/JCI77361","volume":"125","author":"S Tsai","year":"2015","unstructured":"Tsai S, et al. Muscle-specific 4E-BP1 signaling activation improves metabolic parameters during aging and obesity. J Clin Investig. 2015;125(8):2952\u201364.","journal-title":"J Clin Investig"},{"issue":"5","key":"1454_CR127","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.cmet.2013.03.015","volume":"17","author":"P Castets","year":"2013","unstructured":"Castets P, et al. Sustained activation of mTORC1 in skeletal muscle inhibits constitutive and starvation-induced autophagy and causes a severe, late-onset myopathy. Cell Metab. 2013;17(5):731\u201344.","journal-title":"Cell Metab"},{"issue":"1","key":"1454_CR128","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.1038\/s41467-020-18140-1","volume":"11","author":"DJ Ham","year":"2020","unstructured":"Ham DJ, et al. The neuromuscular junction is a focal point of mTORC1 signaling in sarcopenia. Nat Commun. 2020;11(1):4510.","journal-title":"Nat Commun"},{"issue":"6","key":"1454_CR129","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1083\/jcb.200903131","volume":"187","author":"V Risson","year":"2009","unstructured":"Risson V, et al. Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy. J Cell Biol. 2009;187(6):859\u201374.","journal-title":"J Cell Biol"},{"issue":"1","key":"1454_CR130","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/jcsm.12505","volume":"11","author":"AS Ham","year":"2020","unstructured":"Ham AS, et al. mTORC1 signalling is not essential for the maintenance of muscle mass and function in adult sedentary mice. J Cachexia Sarcopenia Muscle. 2020;11(1):259\u201373.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"11","key":"1454_CR131","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1249\/01.mss.0000233797.24035.35","volume":"38","author":"SC Bodine","year":"2006","unstructured":"Bodine SC. mTOR signaling and the molecular adaptation to resistance exercise. Med Sci Sports Exerc. 2006;38(11):1950\u20137.","journal-title":"Med Sci Sports Exerc"},{"key":"1454_CR132","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.omto.2019.12.011","volume":"16","author":"M Schmidt","year":"2020","unstructured":"Schmidt M, Poser C, von Maltzahn J. Wnt7a counteracts cancer cachexia. Mol Therapy - Oncolytics. 2020;16:134\u201346.","journal-title":"Mol Therapy - Oncolytics"},{"issue":"10","key":"1454_CR133","doi-asserted-by":"publisher","first-page":"E1042","DOI":"10.1152\/ajpendo.00410.2012","volume":"304","author":"JP White","year":"2013","unstructured":"White JP, et al. Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK. Am J Physiol Endocrinol Metab. 2013;304(10):E1042\u201352.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"9","key":"1454_CR134","doi-asserted-by":"publisher","first-page":"e24650","DOI":"10.1371\/journal.pone.0024650","volume":"6","author":"JP White","year":"2011","unstructured":"White JP, et al. The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min\/+) mouse. PLoS ONE. 2011;6(9):e24650\u2013e24650.","journal-title":"PLoS ONE"},{"issue":"5","key":"1454_CR135","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3892\/mco.2016.1015","volume":"5","author":"B Gyawali","year":"2016","unstructured":"Gyawali B, et al. Muscle wasting associated with the long-term use of mTOR inhibitors. Mol Clin Oncol. 2016;5(5):641\u20136.","journal-title":"Mol Clin Oncol"},{"issue":"2","key":"1454_CR136","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/jcsm.12054","volume":"7","author":"X Chen","year":"2016","unstructured":"Chen X, et al. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. J Cachexia Sarcopenia Muscle. 2016;7(2):225\u201332.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"1454_CR137","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/jcsm.12854","volume":"13","author":"A Geremia","year":"2022","unstructured":"Geremia A, et al. Activation of Akt\u2013mTORC1 signalling reverts cancer-dependent muscle wasting. J Cachexia Sarcopenia Muscle. 2022;13(1):648\u201361.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1454_CR138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.exger.2015.02.015","volume":"65","author":"MM Markofski","year":"2015","unstructured":"Markofski MM, et al. Effect of age on basal muscle protein synthesis and mTORC1 signaling in a large cohort of young and older men and women. Exp Gerontol. 2015;65:1\u20137.","journal-title":"Exp Gerontol"},{"key":"1454_CR139","doi-asserted-by":"publisher","first-page":"32","DOI":"10.12703\/r\/11-32","volume":"11","author":"SC Bodine","year":"2022","unstructured":"Bodine SC. The role of mTORC1 in the regulation of skeletal muscle mass. Fac Rev. 2022;11:32.","journal-title":"Fac Rev"},{"issue":"45","key":"1454_CR140","doi-asserted-by":"publisher","first-page":"15292","DOI":"10.1074\/jbc.RA120.013634","volume":"295","author":"SJ Russell","year":"2020","unstructured":"Russell SJ, Schneider MF. Alternative signaling pathways from IGF1 or insulin to AKT activation and FOXO1 nuclear efflux in adult skeletal muscle fibers. J Biol Chem. 2020;295(45):15292\u2013306.","journal-title":"J Biol Chem"},{"issue":"1","key":"1454_CR141","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1476-9255-8-13","volume":"8","author":"Q Chen","year":"2011","unstructured":"Chen Q, et al. Insulin alleviates degradation of skeletal muscle protein by inhibiting the ubiquitin-proteasome system in septic rats. J Inflamm. 2011;8(1):13.","journal-title":"J Inflamm"},{"issue":"1","key":"1454_CR142","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13539-011-0051-5","volume":"3","author":"MA Honors","year":"2012","unstructured":"Honors MA, Kinzig KP. The role of insulin resistance in the development of muscle wasting during cancer cachexia. J Cachexia Sarcopenia Muscle. 2012;3(1):5\u201311.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1454_CR143","doi-asserted-by":"publisher","first-page":"ii18","DOI":"10.1093\/annonc\/mdx815","volume":"29","author":"R Dev","year":"2018","unstructured":"Dev R, Bruera E, Dalal S. Insulin resistance and body composition in cancer patients. Ann Oncol. 2018;29:ii18\u201326.","journal-title":"Ann Oncol"},{"issue":"9","key":"1454_CR144","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1210\/en.2006-0251","volume":"147","author":"X Wang","year":"2006","unstructured":"Wang X, et al. Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology. 2006;147(9):4160\u20138.","journal-title":"Endocrinology"},{"issue":"5","key":"1454_CR145","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.clnu.2012.05.003","volume":"31","author":"A Winter","year":"2012","unstructured":"Winter A, MacAdams J, Chevalier S. Normal protein anabolic response to hyperaminoacidemia in insulin-resistant patients with lung cancer cachexia. Clin Nutr. 2012;31(5):765\u201373.","journal-title":"Clin Nutr"},{"issue":"1","key":"1454_CR146","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s43440-020-00179-y","volume":"73","author":"T Masi","year":"2021","unstructured":"Masi T, Patel BM. Altered glucose metabolism and insulin resistance in cancer-induced cachexia: a sweet poison. Pharmacol Rep. 2021;73(1):17\u201330.","journal-title":"Pharmacol Rep"},{"issue":"1","key":"1454_CR147","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1096\/fj.201901107RR","volume":"34","author":"MJ Roberston","year":"2020","unstructured":"Roberston MJ, et al. CRISPR-Cas9\u2013induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression. FASEB J. 2020;34(1):555\u201370.","journal-title":"FASEB J"},{"issue":"3","key":"1454_CR148","doi-asserted-by":"publisher","first-page":"R674","DOI":"10.1152\/ajpregu.00104.2006","volume":"291","author":"P Costelli","year":"2006","unstructured":"Costelli P, et al. IGF-1 is downregulated in experimental cancer cachexia. Am J Physiol Regul Integr Comp Physiol. 2006;291(3):R674\u201383.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"6","key":"1454_CR149","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1053\/j.jrn.2018.11.010","volume":"29","author":"P Delanaye","year":"2019","unstructured":"Delanaye P, et al. Myostatin and insulin-like growth factor 1 are biomarkers of muscle strength, muscle mass, and mortality in patients on hemodialysis. J Ren Nutr. 2019;29(6):511\u201320.","journal-title":"J Ren Nutr"},{"issue":"6","key":"1454_CR150","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1002\/jcsm.12760","volume":"12","author":"H Sakai","year":"2021","unstructured":"Sakai H, et al. Exogenous insulin-like growth factor 1 attenuates cisplatin-induced muscle atrophy in mice. J Cachexia Sarcopenia Muscle. 2021;12(6):1570\u201381.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"4","key":"1454_CR151","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201948791","volume":"21","author":"D Goldbraikh","year":"2020","unstructured":"Goldbraikh D, et al. USP1 deubiquitinates Akt to inhibit PI3K-Akt-FoxO signaling in muscle during prolonged starvation. EMBO Rep. 2020;21(4): e48791.","journal-title":"EMBO Rep"},{"key":"1454_CR152","doi-asserted-by":"publisher","first-page":"3183296","DOI":"10.1155\/2020\/3183296","volume":"2020","author":"Y Tan","year":"2020","unstructured":"Tan Y, et al. Downregulated miR-204 Promotes Skeletal Muscle Regeneration. Biomed Res Int. 2020;2020:3183296.","journal-title":"Biomed Res Int"},{"key":"1454_CR153","doi-asserted-by":"crossref","unstructured":"Li X, et al., MicroRNA-33a negatively regulates myoblast proliferation by targeting IGF1, follistatin and cyclin D1. Biosci Rep, 2020. 40(6).","DOI":"10.1042\/BSR20191327"},{"issue":"11","key":"1454_CR154","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/ng.2772","volume":"45","author":"R Sartori","year":"2013","unstructured":"Sartori R, et al. BMP signaling controls muscle mass. Nat Genet. 2013;45(11):1309\u201318.","journal-title":"Nat Genet"},{"issue":"2","key":"1454_CR155","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1083\/jcb.201211134","volume":"203","author":"CE Winbanks","year":"2013","unstructured":"Winbanks CE, et al. The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass. J Cell Biol. 2013;203(2):345\u201357.","journal-title":"J Cell Biol"},{"key":"1454_CR156","doi-asserted-by":"crossref","unstructured":"Sartori R, et al., Perturbed BMP signaling and denervation promote muscle wasting in cancer cachexia. Sci Transl Med, 2021. 13(605): p. eaay9592.","DOI":"10.1126\/scitranslmed.aay9592"},{"issue":"2","key":"1454_CR157","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3233\/JND-200568","volume":"8","author":"S Schiaffino","year":"2021","unstructured":"Schiaffino S, et al. Molecular Mechanisms of Skeletal Muscle Hypertrophy. J Neuromuscul Dis. 2021;8(2):169\u201383.","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"1454_CR158","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1210\/endrev\/bnab030","volume":"43","author":"BD Rodgers","year":"2022","unstructured":"Rodgers BD, Ward CW. Myostatin\/activin receptor ligands in muscle and the development status of attenuating drugs. Endocr Rev. 2022;43(2):329\u201365.","journal-title":"Endocr Rev"},{"issue":"1","key":"1454_CR159","doi-asserted-by":"publisher","first-page":"E157","DOI":"10.1152\/ajpendo.00193.2009","volume":"297","author":"H Gilson","year":"2009","unstructured":"Gilson H, et al. Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin. Am J Physiol Endocrinol Metab. 2009;297(1):E157\u201364.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1454_CR160","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.neurobiolaging.2021.03.005","volume":"104","author":"CC Iyer","year":"2021","unstructured":"Iyer CC, et al. Follistatin-induced muscle hypertrophy in aged mice improves neuromuscular junction innervation and function. Neurobiol Aging. 2021;104:32\u201341.","journal-title":"Neurobiol Aging"},{"issue":"7","key":"1454_CR161","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.cell.2004.12.007","volume":"119","author":"IW McKinnell","year":"2004","unstructured":"McKinnell IW, Rudnicki MA. Molecular mechanisms of muscle atrophy. Cell. 2004;119(7):907\u201310.","journal-title":"Cell"},{"issue":"3","key":"1454_CR162","doi-asserted-by":"publisher","first-page":"E410","DOI":"10.1152\/ajpendo.00039.2012","volume":"303","author":"A Bonetto","year":"2012","unstructured":"Bonetto A, et al. JAK\/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab. 2012;303(3):E410\u201321.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"12","key":"1454_CR163","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1084\/jem.20111020","volume":"208","author":"TP Braun","year":"2011","unstructured":"Braun TP, et al. Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis. J Exp Med. 2011;208(12):2449\u201363.","journal-title":"J Exp Med"},{"issue":"3","key":"1454_CR164","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1096\/fj.04-2364com","volume":"19","author":"YP Li","year":"2005","unstructured":"Li YP, et al. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1\/MAFbx in skeletal muscle. Faseb J. 2005;19(3):362\u201370.","journal-title":"Faseb J"},{"issue":"13","key":"1454_CR165","doi-asserted-by":"publisher","first-page":"21778","DOI":"10.18632\/oncotarget.15583","volume":"8","author":"A Camperi","year":"2017","unstructured":"Camperi A, et al. Vitamin D and VDR in cancer cachexia and muscle regeneration. Oncotarget. 2017;8(13):21778\u201393.","journal-title":"Oncotarget"},{"key":"1454_CR166","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1186\/1471-2407-14-997","volume":"14","author":"SM Judge","year":"2014","unstructured":"Judge SM, et al. Genome-wide identification of FoxO-dependent gene networks in skeletal muscle during C26 cancer cachexia. BMC Cancer. 2014;14:997.","journal-title":"BMC Cancer"},{"key":"1454_CR167","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.exger.2016.10.003","volume":"87","author":"E Marzetti","year":"2017","unstructured":"Marzetti E, et al. Altered mitochondrial quality control signaling in muscle of old gastric cancer patients with cachexia. Exp Gerontol. 2017;87:92\u20139.","journal-title":"Exp Gerontol"},{"issue":"1","key":"1454_CR168","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cllc.2016.06.003","volume":"18","author":"AJ Murton","year":"2017","unstructured":"Murton AJ, et al. Consequences of late-stage non-small-cell lung cancer cachexia on muscle metabolic processes. Clin Lung Cancer. 2017;18(1):e1\u201311.","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"1454_CR169","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00109-007-0177-2","volume":"85","author":"TL Schmitt","year":"2007","unstructured":"Schmitt TL, et al. Activity of the Akt-dependent anabolic and catabolic pathways in muscle and liver samples in cancer-related cachexia. J Mol Med (Berl). 2007;85(6):647\u201354.","journal-title":"J Mol Med (Berl)"},{"issue":"17","key":"1454_CR170","doi-asserted-by":"publisher","first-page":"11177","DOI":"10.1074\/jbc.M115.641514","volume":"290","author":"KA Silva","year":"2015","unstructured":"Silva KA, et al. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia. J Biol Chem. 2015;290(17):11177\u201387.","journal-title":"J Biol Chem"},{"issue":"1\u20133","key":"1454_CR171","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.regpep.2012.06.003","volume":"178","author":"M Sugiyama","year":"2012","unstructured":"Sugiyama M, et al. Ghrelin improves body weight loss and skeletal muscle catabolism associated with angiotensin II-induced cachexia in mice. Regul Pept. 2012;178(1\u20133):21\u20138.","journal-title":"Regul Pept"},{"issue":"3","key":"1454_CR172","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1053\/j.gastro.2018.10.026","volume":"156","author":"J Yang","year":"2019","unstructured":"Yang J, et al. ZIP4 promotes muscle wasting and cachexia in mice with orthotopic pancreatic tumors by stimulating RAB27B-regulated release of extracellular vesicles from cancer cells. Gastroenterology. 2019;156(3):722\u201334.","journal-title":"Gastroenterology"},{"issue":"4","key":"1454_CR173","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1096\/fj.13-245894","volume":"28","author":"JL Chen","year":"2014","unstructured":"Chen JL, et al. Elevated expression of activins promotes muscle wasting and cachexia. Faseb J. 2014;28(4):1711\u201323.","journal-title":"Faseb J"},{"issue":"10","key":"1454_CR174","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/j.biocel.2005.04.018","volume":"37","author":"DJ Glass","year":"2005","unstructured":"Glass DJ. Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol. 2005;37(10):1974\u201384.","journal-title":"Int J Biochem Cell Biol"},{"issue":"4","key":"1454_CR175","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","volume":"142","author":"X Zhou","year":"2010","unstructured":"Zhou X, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010;142(4):531\u201343.","journal-title":"Cell"},{"issue":"3","key":"1454_CR176","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.bbrc.2009.12.123","volume":"391","author":"ME Benny Klimek","year":"2010","unstructured":"Benny Klimek ME, et al. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem Biophys Res Commun. 2010;391(3):1548\u201354.","journal-title":"Biochem Biophys Res Commun"},{"issue":"16","key":"1454_CR177","doi-asserted-by":"publisher","first-page":"9306","DOI":"10.1073\/pnas.151270098","volume":"98","author":"SJ Lee","year":"2001","unstructured":"Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci U S A. 2001;98(16):9306\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1454_CR178","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1210\/jc.2014-4318","volume":"100","author":"A Loumaye","year":"2015","unstructured":"Loumaye A, et al. Role of Activin A and myostatin in human cancer cachexia. J Clin Endocrinol Metab. 2015;100(5):2030\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6628","key":"1454_CR179","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/387083a0","volume":"387","author":"AC McPherron","year":"1997","unstructured":"McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387(6628):83\u201390.","journal-title":"Nature"},{"issue":"24","key":"1454_CR180","doi-asserted-by":"publisher","first-page":"7344","DOI":"10.1158\/0008-5472.CAN-14-0057","volume":"74","author":"YS Gallot","year":"2014","unstructured":"Gallot YS, et al. Myostatin gene inactivation prevents skeletal muscle wasting in cancer. Cancer Res. 2014;74(24):7344\u201356.","journal-title":"Cancer Res"},{"issue":"11","key":"1454_CR181","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1210\/me.2013-1194","volume":"27","author":"CA Goodman","year":"2013","unstructured":"Goodman CA, et al. Smad3 induces atrogin-1, inhibits mTOR and protein synthesis, and promotes muscle atrophy in vivo. Mol Endocrinol. 2013;27(11):1946\u201357.","journal-title":"Mol Endocrinol"},{"issue":"1","key":"1454_CR182","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s13539-010-0007-1","volume":"1","author":"K Lenk","year":"2010","unstructured":"Lenk K, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle. 2010;1(1):9\u201321.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"6","key":"1454_CR183","doi-asserted-by":"publisher","first-page":"C1248","DOI":"10.1152\/ajpcell.00104.2009","volume":"296","author":"R Sartori","year":"2009","unstructured":"Sartori R, et al. Smad2 and 3 transcription factors control muscle mass in adulthood. Am J Physiol Cell Physiol. 2009;296(6):C1248\u201357.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"6","key":"1454_CR184","doi-asserted-by":"publisher","first-page":"C1258","DOI":"10.1152\/ajpcell.00105.2009","volume":"296","author":"AU Trendelenburg","year":"2009","unstructured":"Trendelenburg AU, et al. Myostatin reduces Akt\/TORC1\/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol. 2009;296(6):C1258\u201370.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"6","key":"1454_CR185","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1093\/gerona\/glr025","volume":"66","author":"A Ratkevicius","year":"2011","unstructured":"Ratkevicius A, et al. Serum concentrations of myostatin and myostatin-interacting proteins do not differ between young and sarcopenic elderly men. J Gerontol A Biol Sci Med Sci. 2011;66(6):620\u20136.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"5","key":"1454_CR186","first-page":"343","volume":"6","author":"KE Yarasheski","year":"2002","unstructured":"Yarasheski KE, et al. Serum myostatin-immunoreactive protein is increased in 60\u201392 year old women and men with muscle wasting. J Nutr Health Aging. 2002;6(5):343\u20138.","journal-title":"J Nutr Health Aging"},{"issue":"5","key":"1454_CR187","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10522-021-09932-z","volume":"22","author":"A Moreira-Pais","year":"2021","unstructured":"Moreira-Pais A, et al. Sarcopenia versus cancer cachexia: the muscle wasting continuum in healthy and diseased aging. Biogerontology. 2021;22(5):459\u201377.","journal-title":"Biogerontology"},{"key":"1454_CR188","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/978-981-13-1435-3_12","volume":"1088","author":"A Thoma","year":"2018","unstructured":"Thoma A, Lightfoot AP. NF-kB and inflammatory cytokine signalling: role in skeletal muscle atrophy. Adv Exp Med Biol. 2018;1088:267\u201379.","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"1454_CR189","first-page":"871","volume":"12","author":"YP Li","year":"1998","unstructured":"Li YP, et al. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. Faseb j. 1998;12(10):871\u201380.","journal-title":"Faseb j"},{"issue":"6","key":"1454_CR190","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1096\/fj.01-0866com","volume":"16","author":"RB Hunter","year":"2002","unstructured":"Hunter RB, et al. Activation of an alternative NF-kappaB pathway in skeletal muscle during disuse atrophy. Faseb J. 2002;16(6):529\u201338.","journal-title":"Faseb J"},{"issue":"15","key":"1454_CR191","doi-asserted-by":"publisher","first-page":"6533","DOI":"10.1128\/MCB.25.15.6533-6545.2005","volume":"25","author":"S Di Marco","year":"2005","unstructured":"Di Marco S, et al. NF-kappa B-mediated MyoD decay during muscle wasting requires nitric oxide synthase mRNA stabilization, HuR protein, and nitric oxide release. Mol Cell Biol. 2005;25(15):6533\u201345.","journal-title":"Mol Cell Biol"},{"issue":"5488","key":"1454_CR192","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1126\/science.289.5488.2363","volume":"289","author":"DC Guttridge","year":"2000","unstructured":"Guttridge DC, et al. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science. 2000;289(5488):2363\u20136.","journal-title":"Science"},{"key":"1454_CR193","doi-asserted-by":"crossref","unstructured":"Fry CS, et al. Glucocorticoids increase skeletal muscle NF-kappaB inducing kinase (NIK): links to muscle atrophy. Physiol Rep, 2016. 4(21).","DOI":"10.14814\/phy2.13014"},{"issue":"5","key":"1454_CR194","doi-asserted-by":"publisher","first-page":"622","DOI":"10.15252\/emmm.201607052","volume":"9","author":"JF Ma","year":"2017","unstructured":"Ma JF, et al. STAT3 promotes IFNgamma\/TNFalpha-induced muscle wasting in an NF-kappaB-dependent and IL-6-independent manner. EMBO Mol Med. 2017;9(5):622\u201337.","journal-title":"EMBO Mol Med"},{"issue":"8","key":"1454_CR195","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1007\/s00432-018-2679-4","volume":"144","author":"T Powrozek","year":"2018","unstructured":"Powrozek T, et al. Relationship between TNF-alpha -1031T\/C gene polymorphism, plasma level of TNF-alpha, and risk of cachexia in head and neck cancer patients. J Cancer Res Clin Oncol. 2018;144(8):1423\u201334.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"1454_CR196","first-page":"787","volume":"20","author":"RA Siddiqui","year":"1990","unstructured":"Siddiqui RA, Williams JF. Tentative identification of the toxohormones of cancer cachexia: roles of vasopressin, prostaglandin E2 and cachectin-TNF. Biochem Int. 1990;20(4):787\u201397.","journal-title":"Biochem Int"},{"issue":"11","key":"1454_CR197","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1002\/ijc.29620","volume":"137","author":"T Matsuyama","year":"2015","unstructured":"Matsuyama T, et al. Tumor inoculation site affects the development of cancer cachexia and muscle wasting. Int J Cancer. 2015;137(11):2558\u201365.","journal-title":"Int J Cancer"},{"issue":"12","key":"1454_CR198","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1177\/002215540205001202","volume":"50","author":"K Kami","year":"2002","unstructured":"Kami K, Senba E. In vivo activation of STAT3 signaling in satellite cells and myofibers in regenerating rat skeletal muscles. J Histochem Cytochem. 2002;50(12):1579\u201389.","journal-title":"J Histochem Cytochem"},{"issue":"1","key":"1454_CR199","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1038\/s41467-019-09746-1","volume":"10","author":"D Sala","year":"2019","unstructured":"Sala D, et al. The Stat3-Fam3a axis promotes muscle stem cell myogenic lineage progression by inducing mitochondrial respiration. Nat Commun. 2019;10(1):1796.","journal-title":"Nat Commun"},{"issue":"8","key":"1454_CR200","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1016\/j.celrep.2016.07.041","volume":"16","author":"H Zhu","year":"2016","unstructured":"Zhu H, et al. STAT3 regulates self-renewal of adult muscle satellite cells during injury-induced muscle regeneration. Cell Rep. 2016;16(8):2102\u201315.","journal-title":"Cell Rep"},{"issue":"1","key":"1454_CR201","doi-asserted-by":"publisher","first-page":"8414","DOI":"10.1038\/s41598-018-26625-9","volume":"8","author":"Z Cramer","year":"2018","unstructured":"Cramer Z, et al. eIF4A inhibition prevents the onset of cytokine-induced muscle wasting by blocking the STAT3 and iNOS pathways. Sci Rep. 2018;8(1):8414.","journal-title":"Sci Rep"},{"issue":"3","key":"1454_CR202","first-page":"171","volume":"19","author":"D Sala","year":"2016","unstructured":"Sala D, Sacco A. Signal transducer and activator of transcription 3 signaling as a potential target to treat muscle wasting diseases. Curr Opin Clin Nutr Metab Care. 2016;19(3):171\u20136.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"11","key":"1454_CR203","first-page":"819","volume":"66","author":"GG Eskiler","year":"2019","unstructured":"Eskiler GG, et al. IL-6 mediated JAK\/STAT3 signaling pathway in cancer patients with cachexia. Bratisl Lek Listy. 2019;66(11):819\u201326.","journal-title":"Bratisl Lek Listy"},{"issue":"7","key":"1454_CR204","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022538","volume":"6","author":"A Bonetto","year":"2011","unstructured":"Bonetto A, et al. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS ONE. 2011;6(7): e22538.","journal-title":"PLoS ONE"},{"key":"1454_CR205","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.semcdb.2016.02.009","volume":"54","author":"TA Zimmers","year":"2016","unstructured":"Zimmers TA, Fishel ML, Bonetto A. STAT3 in the systemic inflammation of cancer cachexia. Semin Cell Dev Biol. 2016;54:28\u201341.","journal-title":"Semin Cell Dev Biol"},{"issue":"4","key":"1454_CR206","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/jcsm.12311","volume":"9","author":"F Pin","year":"2018","unstructured":"Pin F, et al. Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia. J Cachexia Sarcopenia Muscle. 2018;9(4):685\u2013700.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"1454_CR207","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.cmet.2013.07.012","volume":"18","author":"L Zhang","year":"2013","unstructured":"Zhang L, et al. Stat3 activation links a C\/EBP\u03b4 to myostatin pathway to stimulate loss of muscle mass. Cell Metab. 2013;18(3):368\u201379.","journal-title":"Cell Metab"},{"issue":"17","key":"1454_CR208","doi-asserted-by":"publisher","first-page":"11177","DOI":"10.1074\/jbc.M115.641514","volume":"290","author":"KAS Silva","year":"2015","unstructured":"Silva KAS, et al. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia*. J Biol Chem. 2015;290(17):11177\u201387.","journal-title":"J Biol Chem"},{"issue":"1","key":"1454_CR209","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13045-023-01429-1","volume":"16","author":"D Wang","year":"2023","unstructured":"Wang D, et al. LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia. J Hematol Oncol. 2023;16(1):30.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"1454_CR210","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/jcp.24580","volume":"229","author":"M Gilabert","year":"2014","unstructured":"Gilabert M, et al. Pancreatic cancer-induced cachexia is Jak2-dependent in mice. J Cell Physiol. 2014;229(10):1437\u201343.","journal-title":"J Cell Physiol"},{"issue":"5","key":"1454_CR211","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.18632\/oncotarget.2812","volume":"6","author":"F Pretto","year":"2015","unstructured":"Pretto F, et al. Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle. Oncotarget. 2015;6(5):3043\u201354.","journal-title":"Oncotarget"},{"key":"1454_CR212","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/978-1-4939-9027-6_17","volume":"1928","author":"MY Hsu","year":"2019","unstructured":"Hsu MY, Porporato PE, Wyart E. Assessing metabolic dysregulation in muscle during cachexia. Methods Mol Biol. 2019;1928:337\u201352.","journal-title":"Methods Mol Biol"},{"issue":"3","key":"1454_CR213","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1016\/j.bbagen.2012.11.009","volume":"1830","author":"CC Fontes-Oliveira","year":"2013","unstructured":"Fontes-Oliveira CC, et al. Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered energetic efficiency? Biochim Biophys Acta. 2013;1830(3):2770\u20138.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"1454_CR214","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s13539-012-0071-9","volume":"3","author":"CM Julienne","year":"2012","unstructured":"Julienne CM, et al. Cancer cachexia is associated with a decrease in skeletal muscle mitochondrial oxidative capacities without alteration of ATP production efficiency. J Cachexia Sarcopenia Muscle. 2012;3(4):265\u201375.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"10","key":"1454_CR215","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1038\/emboj.2010.60","volume":"29","author":"V Romanello","year":"2010","unstructured":"Romanello V, et al. Mitochondrial fission and remodelling contributes to muscle atrophy. Embo J. 2010;29(10):1774\u201385.","journal-title":"Embo J"},{"issue":"4","key":"1454_CR216","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/jcsm.12294","volume":"9","author":"J Bohlen","year":"2018","unstructured":"Bohlen J, et al. Dysregulation of metabolic-associated pathways in muscle of breast cancer patients: preclinical evaluation of interleukin-15 targeting fatigue. J Cachexia Sarcopenia Muscle. 2018;9(4):701\u201314.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"1454_CR217","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s13539-012-0073-7","volume":"4","author":"BE Phillips","year":"2013","unstructured":"Phillips BE, et al. Effect of colon cancer and surgical resection on skeletal muscle mitochondrial enzyme activity in colon cancer patients: a pilot study. J Cachexia Sarcopenia Muscle. 2013;4(1):71\u20137.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"9","key":"1454_CR218","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.3390\/cancers11091264","volume":"11","author":"GS de Castro","year":"2019","unstructured":"de Castro GS, et al. Human cachexia induces changes in mitochondria, autophagy and apoptosis in the skeletal muscle. Cancers. 2019;11(9):1264.","journal-title":"Cancers"},{"issue":"8","key":"1454_CR219","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/annonc\/mdu085","volume":"25","author":"M Aapro","year":"2014","unstructured":"Aapro M, et al. Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force. Ann Oncol. 2014;25(8):1492\u20139.","journal-title":"Ann Oncol"},{"issue":"8","key":"1454_CR220","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1093\/annonc\/mdu178","volume":"25","author":"S Blauwhoff-Buskermolen","year":"2014","unstructured":"Blauwhoff-Buskermolen S, et al. \u201cPre-cachexia\u201d: a non-existing phenomenon in cancer? Ann Oncol. 2014;25(8):1668\u20139.","journal-title":"Ann Oncol"},{"issue":"3","key":"1454_CR221","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1016\/j.jpainsymman.2021.02.034","volume":"62","author":"KA Bland","year":"2021","unstructured":"Bland KA, et al. Quality of life and symptom burden improve in patients attending a multidisciplinary clinical service for cancer cachexia: a retrospective observational review. J Pain Symptom Manage. 2021;62(3):e164\u201376.","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"1454_CR222","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/SPC.0000000000000176","volume":"9","author":"JJ Borg","year":"2015","unstructured":"Borg JJ, et al. Multimodal management as requirement for the clinical use of anticachexia drugs - a regulatory and a clinical perspective. Curr Opin Support Palliat Care. 2015;9(4):333\u201345.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"2","key":"1454_CR223","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrclinonc.2012.209","volume":"10","author":"K Fearon","year":"2013","unstructured":"Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2013;10(2):90\u20139.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"1454_CR224","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100092","volume":"6","author":"J Arends","year":"2021","unstructured":"Arends J, et al. Cancer cachexia in adult patients: ESMO clinical practice guidelines(). ESMO Open. 2021;6(3): 100092.","journal-title":"ESMO Open"},{"key":"1454_CR225","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1146\/annurev-pharmtox-010818-021041","volume":"59","author":"R Furrer","year":"2019","unstructured":"Furrer R, Handschin C. Muscle wasting diseases: novel targets and treatments. Annu Rev Pharmacol Toxicol. 2019;59:315\u201339.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"22","key":"1454_CR226","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1161\/CIRCULATIONAHA.111.047381","volume":"125","author":"S Gielen","year":"2012","unstructured":"Gielen S, et al. Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging catabolism study. Circulation. 2012;125(22):2716\u201327.","journal-title":"Circulation"},{"issue":"4","key":"1454_CR227","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1152\/japplphysiol.00516.2002","volume":"95","author":"JE Hurst","year":"2003","unstructured":"Hurst JE, Fitts RH. Hindlimb unloading-induced muscle atrophy and loss of function: protective effect of isometric exercise. J Appl Physiol. 2003;95(4):1405\u201317.","journal-title":"J Appl Physiol"},{"issue":"5","key":"1454_CR228","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1139\/H09-093","volume":"34","author":"JP Little","year":"2009","unstructured":"Little JP, Phillips SM. Resistance exercise and nutrition to counteract muscle wasting. Appl Physiol Nutr Metab. 2009;34(5):817\u201328.","journal-title":"Appl Physiol Nutr Metab"},{"issue":"3","key":"1454_CR229","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1177\/109980040100200304","volume":"2","author":"S Al-Majid","year":"2001","unstructured":"Al-Majid S, McCarthy DO. Cancer-induced fatigue and skeletal muscle wasting: the role of exercise. Biol Res Nurs. 2001;2(3):186\u201397.","journal-title":"Biol Res Nurs"},{"issue":"4","key":"1454_CR230","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4251\/wjgo.v7.i4.17","volume":"7","author":"T Aoyagi","year":"2015","unstructured":"Aoyagi T, et al. Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol. 2015;7(4):17\u201329.","journal-title":"World J Gastrointest Oncol"},{"issue":"1","key":"1454_CR231","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/1559827617725283","volume":"13","author":"JP Hardee","year":"2019","unstructured":"Hardee JP, Counts BR, Carson JA. Understanding the role of exercise in cancer cachexia therapy. Am J Lifestyle Med. 2019;13(1):46\u201360.","journal-title":"Am J Lifestyle Med"},{"key":"1454_CR232","doi-asserted-by":"crossref","unstructured":"Morinaga M, et al., Aerobic exercise ameliorates cancer cachexia-induced muscle wasting through adiponectin signaling. Int J Mol Sci, 2021. 22(6).","DOI":"10.3390\/ijms22063110"},{"key":"1454_CR233","doi-asserted-by":"crossref","unstructured":"Wiskemann J, et al., Progressive resistance training to impact physical fitness and body weight in pancreatic cancer patients: a randomized controlled trial. Pancreas, 2019. 48(2).","DOI":"10.1097\/MPA.0000000000001221"},{"issue":"2","key":"1454_CR234","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4103\/0971-5851.60050","volume":"30","author":"P Rajarajeswaran","year":"2009","unstructured":"Rajarajeswaran P, Vishnupriya R. Exercise in cancer. Indian J Med Paediatr Oncol. 2009;30(2):61\u201370.","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"6","key":"1454_CR235","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/MCO.0b013e3283319399","volume":"12","author":"CM Op den Kamp","year":"2009","unstructured":"Op den Kamp CM, et al. Muscle atrophy in cachexia: can dietary protein tip the balance? Curr Opin Clin Nutr Metab Care. 2009;12(6):611\u20136.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"2","key":"1454_CR236","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1200\/JCO.2002.20.2.567","volume":"20","author":"A Jatoi","year":"2002","unstructured":"Jatoi A, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. 2002;20(2):567\u201373.","journal-title":"J Clin Oncol"},{"key":"1454_CR237","first-page":"CD004310","volume":"3","author":"V RuizGarcia","year":"2013","unstructured":"RuizGarcia V, et al. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2013;3:CD004310.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"1454_CR238","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/S0959-8049(96)00486-8","volume":"33","author":"G Mantovani","year":"1997","unstructured":"Mantovani G, et al. Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia\/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur J Cancer. 1997;33(4):602\u20137.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1454_CR239","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2165\/00003495-200161040-00004","volume":"61","author":"G Mantovani","year":"2001","unstructured":"Mantovani G, et al. Managing cancer-related anorexia\/cachexia. Drugs. 2001;61(4):499\u2013514.","journal-title":"Drugs"},{"issue":"6","key":"1454_CR240","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.jpainsymman.2021.05.017","volume":"62","author":"CN Hunter","year":"2021","unstructured":"Hunter CN, et al. Mirtazapine in cancer-associated anorexia and cachexia: a double-blind placebo-controlled randomized trial. J Pain Symptom Manage. 2021;62(6):1207\u201315.","journal-title":"J Pain Symptom Manage"},{"issue":"7","key":"1454_CR241","first-page":"3347","volume":"45","author":"WK Evans","year":"1985","unstructured":"Evans WK, et al. Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. Cancer Res. 1985;45(7):3347\u201353.","journal-title":"Cancer Res"},{"issue":"3","key":"1454_CR242","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<553::AID-CNCR18>3.0.CO;2-0","volume":"82","author":"JP Simons","year":"1998","unstructured":"Simons JP, et al. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial. Cancer. 1998;82(3):553\u201360.","journal-title":"Cancer"},{"issue":"1","key":"1454_CR243","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.metabol.2003.06.004","volume":"53","author":"T Hanada","year":"2004","unstructured":"Hanada T, et al. Upregulation of ghrelin expression in cachectic nude mice bearing human melanoma cells. Metabolism. 2004;53(1):84\u20138.","journal-title":"Metabolism"},{"issue":"3","key":"1454_CR244","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.lungcan.2009.02.006","volume":"66","author":"EM Karapanagiotou","year":"2009","unstructured":"Karapanagiotou EM, et al. Increased serum levels of ghrelin at diagnosis mediate body weight loss in non-small cell lung cancer (NSCLC) patients. Lung Cancer. 2009;66(3):393\u20138.","journal-title":"Lung Cancer"},{"issue":"23","key":"1454_CR245","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.3748\/wjg.14.3633","volume":"14","author":"M Kerem","year":"2008","unstructured":"Kerem M, et al. Adipokines and ghrelin in gastric cancer cachexia. World J Gastroenterol. 2008;14(23):3633\u201341.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"1454_CR246","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10147-008-0856-1","volume":"14","author":"M Takahashi","year":"2009","unstructured":"Takahashi M, et al. Ghrelin and leptin levels in cachectic patients with cancer of the digestive organs. Int J Clin Oncol. 2009;14(4):315\u201320.","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"1454_CR247","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2169\/internalmedicine.45.1402","volume":"45","author":"N Nagaya","year":"2006","unstructured":"Nagaya N, Kojima M, Kangawa K. Ghrelin, a novel growth hormone-releasing peptide, in the treatment of cardiopulmonary-associated cachexia. Intern Med. 2006;45(3):127\u201334.","journal-title":"Intern Med"},{"issue":"6","key":"1454_CR248","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1210\/en.2007-0016","volume":"148","author":"MD DeBoer","year":"2007","unstructured":"DeBoer MD, et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology. 2007;148(6):3004\u201312.","journal-title":"Endocrinology"},{"issue":"12","key":"1454_CR249","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1517\/13543784.2014.942729","volume":"23","author":"AM Dingemans","year":"2014","unstructured":"Dingemans AM, et al. Phase II drugs that are currently in development for the treatment of cachexia. Expert Opin Investig Drugs. 2014;23(12):1655\u201369.","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"1454_CR250","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/0092-8674(87)90028-6","volume":"50","author":"A Oliff","year":"1987","unstructured":"Oliff A, et al. Tumors secreting human TNF\/cachectin induce cachexia in mice. Cell. 1987;50(4):555\u201363.","journal-title":"Cell"},{"issue":"6","key":"1454_CR251","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1002\/cncr.22944","volume":"110","author":"A Jatoi","year":"2007","unstructured":"Jatoi A, et al. A placebo-controlled double blind trial of etanercept for the cancer anorexia\/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. Cancer. 2007;110(6):1396\u2013403.","journal-title":"Cancer"},{"issue":"2","key":"1454_CR252","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.lungcan.2009.06.020","volume":"68","author":"A Jatoi","year":"2010","unstructured":"Jatoi A, et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and\/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer. 2010;68(2):234\u20139.","journal-title":"Lung Cancer"},{"issue":"8","key":"1454_CR253","first-page":"512","volume":"149","author":"I Gueta","year":"2010","unstructured":"Gueta I, Altman A, Shoenfeld Y. The effect of blocking TNF-alpha in patients with cancer-related cachexia and anorexia. Harefuah. 2010;149(8):512\u201351.","journal-title":"Harefuah"},{"key":"1454_CR254","first-page":"008664","volume":"4","author":"J Reid","year":"2012","unstructured":"Reid J, et al. Thalidomide for managing cancer cachexia. Cochrane Database Syst Rev. 2012;4:008664.","journal-title":"Cochrane Database Syst Rev"},{"issue":"25","key":"1454_CR255","doi-asserted-by":"publisher","first-page":"22382","DOI":"10.1074\/jbc.M100938200","volume":"276","author":"JA Keifer","year":"2001","unstructured":"Keifer JA, et al. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem. 2001;276(25):22382\u20137.","journal-title":"J Biol Chem"},{"issue":"2","key":"1454_CR256","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1152\/physrev.00016.2008","volume":"89","author":"MJ Tisdale","year":"2009","unstructured":"Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev. 2009;89(2):381\u2013410.","journal-title":"Physiol Rev"},{"issue":"5","key":"1454_CR257","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1002\/1097-0142(197511)36:5<1888::AID-CNCR2820360546>3.0.CO;2-Y","volume":"36","author":"WD DeWys","year":"1975","unstructured":"DeWys WD, Walters K. Abnormalities of taste sensation in cancer patients. Cancer. 1975;36(5):1888\u201396.","journal-title":"Cancer"},{"issue":"11","key":"1454_CR258","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1200\/JCO.1995.13.11.2856","volume":"13","author":"RM Goldberg","year":"1995","unstructured":"Goldberg RM, et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol. 1995;13(11):2856\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1454_CR259","first-page":"18","volume":"6","author":"B Wiedenmann","year":"2008","unstructured":"Wiedenmann B, et al. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol. 2008;6(1):18\u201325.","journal-title":"J Support Oncol"},{"issue":"12","key":"1454_CR260","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1517\/14712598.2011.627850","volume":"11","author":"TJ Bayliss","year":"2011","unstructured":"Bayliss TJ, et al. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther. 2011;11(12):1663\u20138.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"1454_CR261","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00109-009-0547-z","volume":"88","author":"G Mantovani","year":"2010","unstructured":"Mantovani G, et al. Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med (Berl). 2010;88(1):85\u201392.","journal-title":"J Mol Med (Berl)"},{"issue":"6","key":"1454_CR262","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1126\/scitranslmed.3000112","volume":"1","author":"J Kota","year":"2009","unstructured":"Kota J, et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med. 2009;1(6):6\u201315.","journal-title":"Sci Transl Med"},{"issue":"4","key":"1454_CR263","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1128\/MCB.01307-13","volume":"34","author":"E Lach-Trifilieff","year":"2014","unstructured":"Lach-Trifilieff E, et al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol. 2014;34(4):606\u201318.","journal-title":"Mol Cell Biol"},{"issue":"6914","key":"1454_CR264","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/nature01154","volume":"420","author":"S Bogdanovich","year":"2002","unstructured":"Bogdanovich S, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature. 2002;420(6914):418\u201321.","journal-title":"Nature"},{"issue":"3","key":"1454_CR265","first-page":"579","volume":"69","author":"MW Hamrick","year":"2010","unstructured":"Hamrick MW, et al. Recombinant myostatin (GDF-8) propeptide enhances the repair and regeneration of both muscle and bone in a model of deep penetrant musculoskeletal injury. J Trauma. 2010;69(3):579\u201383.","journal-title":"J Trauma"},{"issue":"3","key":"1454_CR266","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1161\/CIRCULATIONAHA.109.882068","volume":"121","author":"J Heineke","year":"2010","unstructured":"Heineke J, et al. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation. 2010;121(3):419\u201325.","journal-title":"Circulation"},{"issue":"11","key":"1454_CR267","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1038\/ijo.2009.162","volume":"33","author":"I Akpan","year":"2009","unstructured":"Akpan I, et al. The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity. Int J Obes (Lond). 2009;33(11):1265\u201373.","journal-title":"Int J Obes (Lond)"},{"issue":"9","key":"1454_CR268","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1113\/jphysiol.2011.226001","volume":"590","author":"Q Wang","year":"2012","unstructured":"Wang Q, McPherron AC. Myostatin inhibition induces muscle fibre hypertrophy prior to satellite cell activation. J Physiol. 2012;590(9):2151\u201365.","journal-title":"J Physiol"},{"issue":"5","key":"1454_CR269","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1096\/fj.10-176917","volume":"25","author":"L Zhang","year":"2011","unstructured":"Zhang L, et al. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J. 2011;25(5):1653\u201363.","journal-title":"FASEB J"},{"issue":"9","key":"1454_CR270","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1474-4422(19)30200-5","volume":"18","author":"MG Hanna","year":"2019","unstructured":"Hanna MG, et al. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol. 2019;18(9):834\u201344.","journal-title":"Lancet Neurol"},{"issue":"7675","key":"1454_CR271","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nature24042","volume":"550","author":"JY Hsu","year":"2017","unstructured":"Hsu JY, et al. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. Nature. 2017;550(7675):255\u20139.","journal-title":"Nature"},{"issue":"10","key":"1454_CR272","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/nm.4393","volume":"23","author":"PJ Emmerson","year":"2017","unstructured":"Emmerson PJ, et al. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nat Med. 2017;23(10):1215\u20139.","journal-title":"Nat Med"},{"key":"1454_CR273","doi-asserted-by":"crossref","unstructured":"Molfino A, et al., Association between growth differentiation factor-15 (GDF-15) serum levels, anorexia and low muscle mass among cancer patients. Cancers (Basel), 2020. 13(1).","DOI":"10.3390\/cancers13010099"},{"issue":"4","key":"1454_CR274","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.7150\/jca.50376","volume":"12","author":"DS Ahmed","year":"2021","unstructured":"Ahmed DS, et al. GDF15\/GFRAL pathway as a metabolic signature for cachexia in patients with cancer. J Cancer. 2021;12(4):1125\u201332.","journal-title":"J Cancer"},{"issue":"11","key":"1454_CR275","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/nm1677","volume":"13","author":"H Johnen","year":"2007","unstructured":"Johnen H, et al. Tumor-induced anorexia and weight loss are mediated by the TGF-\u03b2 superfamily cytokine MIC-1. Nat Med. 2007;13(11):1333\u201340.","journal-title":"Nat Med"},{"issue":"1","key":"1454_CR276","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111947","volume":"42","author":"JY Kim-Muller","year":"2023","unstructured":"Kim-Muller JY, et al. GDF15 neutralization restores muscle function and physical performance in a mouse model of cancer cachexia. Cell Rep. 2023;42(1): 111947.","journal-title":"Cell Rep"},{"issue":"10","key":"1454_CR277","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1007\/s00018-011-0883-3","volume":"69","author":"V Dubois","year":"2012","unstructured":"Dubois V, et al. Androgens and skeletal muscle: cellular and molecular action mechanisms underlying the anabolic actions. Cell Mol Life Sci. 2012;69(10):1651\u201367.","journal-title":"Cell Mol Life Sci"},{"key":"1454_CR278","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.mce.2017.02.031","volume":"447","author":"ML Rossetti","year":"2017","unstructured":"Rossetti ML, Steiner JL, Gordon BS. Androgen-mediated regulation of skeletal muscle protein balance. Mol Cell Endocrinol. 2017;447:35\u201344.","journal-title":"Mol Cell Endocrinol"},{"issue":"9","key":"1454_CR279","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1249\/MSS.0b013e31828cf5f3","volume":"45","author":"C Basualto-Alarcon","year":"2013","unstructured":"Basualto-Alarcon C, et al. Testosterone signals through mTOR and androgen receptor to induce muscle hypertrophy. Med Sci Sports Exerc. 2013;45(9):1712\u201320.","journal-title":"Med Sci Sports Exerc"},{"issue":"32","key":"1454_CR280","doi-asserted-by":"publisher","first-page":"14327","DOI":"10.1073\/pnas.1009536107","volume":"107","author":"C Chambon","year":"2010","unstructured":"Chambon C, et al. Myocytic androgen receptor controls the strength but not the mass of limb muscles. Proc Natl Acad Sci U S A. 2010;107(32):14327\u201332.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1454_CR281","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.mce.2012.10.019","volume":"365","author":"JP White","year":"2013","unstructured":"White JP, et al. Testosterone regulation of Akt\/mTORC1\/FoxO3a signaling in skeletal muscle. Mol Cell Endocrinol. 2013;365(2):174\u201386.","journal-title":"Mol Cell Endocrinol"},{"issue":"52","key":"1454_CR282","doi-asserted-by":"publisher","first-page":"36367","DOI":"10.1074\/jbc.M109.049734","volume":"284","author":"A Schmidt","year":"2009","unstructured":"Schmidt A, et al. Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands. J Biol Chem. 2009;284(52):36367\u201376.","journal-title":"J Biol Chem"},{"issue":"3","key":"1454_CR283","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s13539-011-0034-6","volume":"2","author":"JT Dalton","year":"2011","unstructured":"Dalton JT, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011;2(3):153\u201361.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"4","key":"1454_CR284","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1470-2045(13)70055-X","volume":"14","author":"AS Dobs","year":"2013","unstructured":"Dobs AS, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14(4):335\u201345.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1454_CR285","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/gerona\/gls078","volume":"68","author":"S Basaria","year":"2013","unstructured":"Basaria S, et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2013;68(1):87\u201395.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"6","key":"1454_CR286","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11912-016-0522-0","volume":"18","author":"J Crawford","year":"2016","unstructured":"Crawford J, et al. Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER Trials). Curr Oncol Rep. 2016;18(6):37.","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"1454_CR287","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/mus.10092","volume":"25","author":"RT Hinkle","year":"2002","unstructured":"Hinkle RT, et al. Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the beta2-adrenergic receptor. Muscle Nerve. 2002;25(5):729\u201334.","journal-title":"Muscle Nerve"},{"issue":"3","key":"1454_CR288","doi-asserted-by":"publisher","first-page":"R1076","DOI":"10.1152\/ajpregu.2000.279.3.R1076","volume":"279","author":"P Rajab","year":"2000","unstructured":"Rajab P, et al. Skeletal muscle myosin heavy chain isoforms and energy metabolism after clenbuterol treatment in the rat. Am J Physiol Regul Integr Comp Physiol. 2000;279(3):R1076\u201381.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"18","key":"1454_CR289","doi-asserted-by":"publisher","first-page":"6725","DOI":"10.1158\/0008-5472.CAN-04-0425","volume":"64","author":"S Busquets","year":"2004","unstructured":"Busquets S, et al. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res. 2004;64(18):6725\u201331.","journal-title":"Cancer Res"},{"issue":"1","key":"1454_CR290","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3892\/ol.2011.442","volume":"3","author":"S Busquets","year":"2012","unstructured":"Busquets S, et al. Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats. Oncol Lett. 2012;3(1):185\u20139.","journal-title":"Oncol Lett"},{"issue":"1","key":"1454_CR291","doi-asserted-by":"publisher","first-page":"E123","DOI":"10.1152\/ajpendo.00188.2011","volume":"302","author":"DA Goncalves","year":"2012","unstructured":"Goncalves DA, et al. Clenbuterol suppresses proteasomal and lysosomal proteolysis and atrophy-related genes in denervated rat soleus muscles independently of Akt. Am J Physiol Endocrinol Metab. 2012;302(1):E123\u201333.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"1454_CR292","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/jcsm.12126","volume":"7","author":"AJ Stewart Coats","year":"2016","unstructured":"Stewart Coats AJ, et al. Espindolol for the treatment and prevention of cachexia in patients with stage III\/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial). J Cachexia Sarcopenia Muscle. 2016;7(3):355\u201365.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1454_CR293","doi-asserted-by":"crossref","unstructured":"Li W, et al., Role for Plant-Derived Antioxidants in Attenuating Cancer Cachexia. Antioxidants (Basel), 2022. 11(2).","DOI":"10.3390\/antiox11020183"},{"issue":"1","key":"1454_CR294","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1631\/jzus.B1800171","volume":"20","author":"B Park","year":"2019","unstructured":"Park B, et al. A systematic review of herbal medicines for the treatment of cancer cachexia in animal models. J Zhejiang Univ Sci B. 2019;20(1):9\u201322.","journal-title":"J Zhejiang Univ Sci B"},{"issue":"6","key":"1454_CR295","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2006.11.013","volume":"127","author":"M Lagouge","year":"2006","unstructured":"Lagouge M, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;127(6):1109\u201322.","journal-title":"Cell"},{"issue":"2","key":"1454_CR296","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.intimp.2014.02.002","volume":"19","author":"DT Wang","year":"2014","unstructured":"Wang DT, et al. Resveratrol prevents TNF-alpha-induced muscle atrophy via regulation of Akt\/mTOR\/FoxO1 signaling in C2C12 myotubes. Int Immunopharmacol. 2014;19(2):206\u201313.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"1454_CR297","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/01635581.2011.563032","volume":"63","author":"S Shadfar","year":"2011","unstructured":"Shadfar S, et al. Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo. Nutr Cancer. 2011;63(5):749\u201362.","journal-title":"Nutr Cancer"},{"issue":"1","key":"1454_CR298","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.bbrc.2011.11.154","volume":"417","author":"N Alamdari","year":"2012","unstructured":"Alamdari N, et al. Resveratrol prevents dexamethasone-induced expression of the muscle atrophy-related ubiquitin ligases atrogin-1 and MuRF1 in cultured myotubes through a SIRT1-dependent mechanism. Biochem Biophys Res Commun. 2012;417(1):528\u201333.","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"1454_CR299","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083518","volume":"8","author":"BT Bennett","year":"2013","unstructured":"Bennett BT, Mohamed JS, Alway SE. Effects of resveratrol on the recovery of muscle mass following disuse in the plantaris muscle of aged rats. PLoS ONE. 2013;8(12): e83518.","journal-title":"PLoS ONE"},{"issue":"1","key":"1454_CR300","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/cvr\/cvq355","volume":"90","author":"CE Schreiner","year":"2011","unstructured":"Schreiner CE, et al. Resveratrol blocks Akt activation in angiotensin II- or EGF-stimulated vascular smooth muscle cells in a redox-independent manner. Cardiovasc Res. 2011;90(1):140\u20137.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"1454_CR301","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.nut.2008.09.002","volume":"25","author":"N Alamdari","year":"2009","unstructured":"Alamdari N, O\u2019Neal P, Hasselgren PO. Curcumin and muscle wasting: a new role for an old drug? Nutrition. 2009;25(2):125\u20139.","journal-title":"Nutrition"},{"key":"1454_CR302","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/317851","volume":"2008","author":"V Poylin","year":"2008","unstructured":"Poylin V, et al. The NF-kappaB inhibitor curcumin blocks sepsis-induced muscle proteolysis. Mediators Inflamm. 2008;2008: 317851.","journal-title":"Mediators Inflamm"},{"issue":"4","key":"1454_CR303","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/jcb.21060","volume":"100","author":"B Jin","year":"2007","unstructured":"Jin B, Li YP. Curcumin prevents lipopolysaccharide-induced atrogin-1\/MAFbx upregulation and muscle mass loss. J Cell Biochem. 2007;100(4):960\u20139.","journal-title":"J Cell Biochem"},{"issue":"12","key":"1454_CR304","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.neo.2021.11.008","volume":"23","author":"YT Wijaya","year":"2021","unstructured":"Wijaya YT, et al. Amelioration of muscle wasting by gintonin in cancer cachexia. Neoplasia. 2021;23(12):1307\u201317.","journal-title":"Neoplasia"},{"issue":"6","key":"1454_CR305","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1002\/jcsm.13084","volume":"13","author":"YT Wijaya","year":"2022","unstructured":"Wijaya YT, et al. Ginsenoside Rd ameliorates muscle wasting by suppressing the signal transducer and activator of transcription 3 pathway. J Cachexia Sarcopenia Muscle. 2022;13(6):3149\u201362.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1454_CR306","doi-asserted-by":"crossref","unstructured":"Fry CS, et al., Glucocorticoids increase skeletal muscle NF-\u03baB inducing kinase (NIK): links to muscle atrophy. Physiol Rep, 2016. 4(21).","DOI":"10.14814\/phy2.13014"},{"issue":"5","key":"1454_CR307","doi-asserted-by":"publisher","first-page":"622","DOI":"10.15252\/emmm.201607052","volume":"9","author":"JF Ma","year":"2017","unstructured":"Ma JF, et al. STAT3 promotes IFN\u03b3\/TNF\u03b1-induced muscle wasting in an NF-\u03baB-dependent and IL-6-independent manner. EMBO Mol Med. 2017;9(5):622\u201337.","journal-title":"EMBO Mol Med"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01454-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-023-01454-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01454-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T16:04:14Z","timestamp":1684771454000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-023-01454-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":307,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1454"],"URL":"https:\/\/doi.org\/10.1186\/s13045-023-01454-0","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,22]]},"assertion":[{"value":"3 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to participate."}},{"value":"The content of this manuscript has not been previously published and is not under consideration for publication elsewhere.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}